Literature DB >> 24035494

Life tables adjusted for comorbidity more accurately estimate noncancer survival for recently diagnosed cancer patients.

Angela B Mariotto1, Zhuoqiao Wang, Carrie N Klabunde, Hyunsoon Cho, Barnali Das, Eric J Feuer.   

Abstract

OBJECTIVES: To provide cancer patients and clinicians with more accurate estimates of a patient's life expectancy with respect to noncancer mortality, we estimated comorbidity-adjusted life tables and health-adjusted age. STUDY DESIGN AND
SETTING: Using data from the Surveillance Epidemiology and End Results-Medicare database, we estimated comorbidity scores that reflect the health status of people who are 66 years of age and older in the year before cancer diagnosis. Noncancer survival by comorbidity score was estimated for each age, race, and sex. Health-adjusted age was estimated by systematically comparing the noncancer survival models with US life tables.
RESULTS: Comorbidity, cancer status, sex, and race are all important predictors of noncancer survival; however, their relative impact on noncancer survival decreases as age increases. Survival models by comorbidity better predicted noncancer survival than the US life tables. The health-adjusted age and national life tables can be consulted to provide an approximate estimate of a person's life expectancy, for example, the health-adjusted age of a black man aged 75 years with no comorbidities is 67 years, giving him a life expectancy of 13 years.
CONCLUSION: The health-adjusted age and the life tables adjusted by age, race, sex, and comorbidity can provide important information to facilitate decision making about treatment for cancer and other conditions. Published by Elsevier Inc.

Entities:  

Keywords:  Cancer; Comorbidity; Health-adjusted age; Life expectancy; Life tables; SEER–Medicare; Survival

Mesh:

Year:  2013        PMID: 24035494      PMCID: PMC3934002          DOI: 10.1016/j.jclinepi.2013.07.002

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  26 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  The relative survival rate: a statistical methodology.

Authors:  F EDERER; L M AXTELL; S J CUTLER
Journal:  Natl Cancer Inst Monogr       Date:  1961-09

3.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

4.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

5.  Predicting life span for applicants to inpatient hospice.

Authors:  L E Forster; J Lynn
Journal:  Arch Intern Med       Date:  1988-12

6.  Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?

Authors:  C M Kelly; K I Pritchard; M Trudeau; E Andreopoulou; K Hess; L Pusztai
Journal:  Ann Oncol       Date:  2011-03-15       Impact factor: 32.976

7.  Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival.

Authors:  K A Cronin; E J Feuer
Journal:  Stat Med       Date:  2000-07-15       Impact factor: 2.373

8.  Accuracy of life tables in predicting overall survival in patients after radical prostatectomy.

Authors:  Jochen Walz; Nazareno Suardi; Shahrokh F Shariat; Claudio Jeldres; Paul Perrotte; Markus Graefen; Hughes Widmer; Philippe Arjane; Luc Valiquette; Georg Hutterer; Fred Saad; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2008-04-02       Impact factor: 5.588

Review 9.  A systematic review of physicians' survival predictions in terminally ill cancer patients.

Authors:  Paul Glare; Kiran Virik; Mark Jones; Malcolm Hudson; Steffen Eychmuller; John Simes; Nicholas Christakis
Journal:  BMJ       Date:  2003-07-26

10.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

View more
  23 in total

1.  Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Authors:  Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin
Journal:  Ann Intern Med       Date:  2016-01-12       Impact factor: 25.391

2.  Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores.

Authors:  Young Chandler; Jinani C Jayasekera; Clyde B Schechter; Claudine Isaacs; Christopher J Cadham; Jeanne S Mandelblatt
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

Review 3.  A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.

Authors:  Matthew Kent; Andrew J Vickers
Journal:  J Urol       Date:  2014-11-15       Impact factor: 7.450

Review 4.  Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.

Authors:  Jesse D Sammon; Firas Abdollah; Anthony D'Amico; Matthew Gettman; Alexander Haese; Nazareno Suardi; Andrew Vickers; Quoc-Dien Trinh
Journal:  Eur Urol       Date:  2015-03-26       Impact factor: 20.096

5.  External validation of a nomogram for the prediction of 10-year life expectancy in candidates for radical prostatectomy.

Authors:  Sophie Knipper; David Pröwrock; Zhe Tian; Hans Heinzer; Derya Tilki; Pierre Karakiewicz; Markus Graefen
Journal:  World J Urol       Date:  2019-03-04       Impact factor: 4.226

6.  Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.

Authors:  Laura L Hester; Steven I Park; William A Wood; Til Stürmer; M Alan Brookhart; Jennifer L Lund
Journal:  Cancer       Date:  2018-12-11       Impact factor: 6.860

7.  Cancer survival: an overview of measures, uses, and interpretation.

Authors:  Angela B Mariotto; Anne-Michelle Noone; Nadia Howlader; Hyunsoon Cho; Gretchen E Keel; Jessica Garshell; Steven Woloshin; Lisa M Schwartz
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

8.  Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.

Authors:  Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward
Journal:  Cancer       Date:  2013-12-16       Impact factor: 6.860

9.  Anticipating the "Silver Tsunami": Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States.

Authors:  Shirley M Bluethmann; Angela B Mariotto; Julia H Rowland
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-07       Impact factor: 4.254

10.  Impact of comorbidities at diagnosis on prostate cancer treatment and survival.

Authors:  Katarina Luise Matthes; Manuela Limam; Giulia Pestoni; Leonhard Held; Dimitri Korol; Sabine Rohrmann
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.